Nine companies are expected annual net profit rose over 100%

Pharmaceutical Network January 19 hearing recently, the announcement of the performance of pharmaceutical health listed companies have been released one after another.Yealth yuan, Livzon Group, letter Litas, Ruikang pharmaceutical companies such as the annual net profit of more than 1000000000 yuan.Realized the list Watson bio-industry season notice 'big face', from the previous performance of 50 million yuan to pre-losing more than 500 million yuan.

According to the available data, the reporter counted 100 medicines health Listed companies announced the results of the forecast, of which pre-earnings accounted for up to Bacheng enterprises. Efan Pharmaceutical, Health yuan, Livzon Group, the new and into, Shanghai Lai Shi, Shin Litas, Biokang shares, Ruikang pharmaceutical companies are expected to Annual net profit of more than 1 billion yuan.

Among the pre-increased listed companies, Berry Gene, which registered capital markets last year, is expected to have the highest increase - net profit attributable to shareholders of listed companies increased by 5594.6% ~ 6311.29% in 2017. In response, Berry Gene said that in 2017 August 10, the company completed a major asset restructuring project, the third quarter of Berry and Health will become the financial parent company, the merger of its financial data.According to the first three quarters of 2017 and Berry Health has achieved financial data, pre Estimated 2017 annual net profit of 230 million yuan to 260 million yuan.

In addition, nine companies including Tiger Pharmaceutical, Pharmaceutical Technology, Zixin Pharmaceutical, Ya Bao Pharmaceutical, Runda Medical, Health Yuan, Yongan Pharmaceutical, Livzon Pharmaceutical Group, Yisheng Pharmaceutical Co., Ltd. are expected to report the largest annual net profit growth over the same period of the previous year 100%.

In the pre-loss and pre-losing areas, including Xiang Xue Pharmaceutical, Lisheng Pharmaceutical, Hansen Pharmaceutical, Coron Pharmaceutical, and Ren Science and Technology, Longjin Pharmaceutical, Hai Sike, Watson Biological, nine medical and other companies, including Watson The change of net profit attributable to shareholders of listed company of Bio and Jiu'an Medical was -864.28% ~ -857.18% and -1134.63% ~ -996.68% respectively.

January 5, Watson Biological Release Bulletin said the company expects net profit attributable to shareholders of listed companies for a loss of 534 million yuan to 539 million yuan in 2017. However, according to the company November 2, 2017 Interim announcement of "2017 Annual Performance Forecast" is expected in 2017 attributable to shareholders of listed companies net profit of 30 million yuan to 51 million yuan, a profit of 70.46 million yuan over the same period last year dropped 27% ~ 57%.

Watson explained that the main reason is that the Company will bear the accounts receivable arising from the liability of Hebei Daan Pharmaceutical Co., Ltd. Therefore, it needs to accrue the impairment loss of assets caused by impairment of long-term equity investment and bad debt provision. Watson Biologicals estimates that the Company incurred a loss of RMB344 million from the accounts receivable arising from the Da'an Reparation for Damages in Hebei and provided an impairment of long-term equity investments and an impairment loss of RMB123 million from the provision for bad debts.

Reporter access to information found Watson biological performance forecast 'change face' is not the first time in the 2015 annual performance forecast Watson Biology had expected a loss of 455 million to 460 million yuan this year, the final disclosure of the annual report, the actual reported Loss of up to 841 million yuan.